[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fKLhVaWZoYtRW17ZlQvujVqh_acAMFfdpXTEdweuzwIU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"Ethicon, Inc.",[4],66,false,5,16,20201,0,45,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Hemorrhage",8,{"name":18,"count":19},"Stress Urinary Incontinence",6,{"name":21,"count":8},"Pelvic Organ Prolapse",{"name":23,"count":24},"Soft Tissue Bleeding",4,{"name":26,"count":24},"Hemostasis",{"name":28,"count":29},"Non-Small Cell Lung Cancer",3,{"name":31,"count":29},"Uterine Fibroids",{"name":33,"count":29},"Cancer of the Lung",[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,83,119,164,199,235,270,299,324,349,375,393,417,442,460,485],{"intervention":44,"totalTrials":45,"cells":46},"Bioseal Fibrin Sealant",2,{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":51,"PHASE3":53,"PHASE4":55,"NA":81},{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[57,69],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"primaryCompletion":62,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":68},"NCT02034799","Phase IV Bioseal Study in Brain Tumor Surgery","COMPLETED",[40],"2014-08-01","2014-09-01","2013-11-01",256,[26,67],"Meningioma Surgery",[44],{"nctId":70,"briefTitle":71,"status":60,"phases":72,"primaryCompletion":73,"completion":74,"start":75,"enrollment":76,"conditions":77,"interventions":80},"NCT02094885","The Bioseal Vascular Study",[40],"2014-11-01","2014-12-01","2014-02-01",252,[78,79,15],"Cardiovascular Bleeding","Vascular Bleeding",[44],{"trials":82,"activeCount":11},[],{"intervention":84,"totalTrials":45,"cells":85},"EVARREST™ Fibrin Sealant Patch",{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":106,"NA":117},{"trials":87,"activeCount":11},[],{"trials":89,"activeCount":11},[],{"trials":91,"activeCount":11},[],{"trials":93,"activeCount":11},[94],{"nctId":95,"briefTitle":96,"status":60,"phases":97,"primaryCompletion":98,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":104},"NCT02040428","The Fibrin Pad CV Phase III Study",[39],"2015-07-01","2015-09-01","2014-01-01",156,[103],"Cardiovascular Disease",[84,105],"Topical hemostat",{"trials":107,"activeCount":11},[108],{"nctId":109,"briefTitle":110,"status":60,"phases":111,"primaryCompletion":112,"completion":99,"start":113,"enrollment":114,"conditions":115,"interventions":116},"NCT01902459","EVARREST™ Fibrin Sealant Patch Post-Market Study",[40],"2015-08-01","2013-07-01",150,[15,23],[84],{"trials":118,"activeCount":11},[],{"intervention":120,"totalTrials":29,"cells":121},"Fibrin Pad",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":138,"PHASE4":160,"NA":162},{"trials":123,"activeCount":11},[],{"trials":125,"activeCount":11},[],{"trials":127,"activeCount":11},[128],{"nctId":129,"briefTitle":130,"status":60,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT00658723","The Fibrin Patch Soft Tissue Study",[38],"2009-04","2009-05","2008-03",141,[26],[120],{"trials":139,"activeCount":11},[140,150],{"nctId":141,"briefTitle":142,"status":60,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT00977925","The Severe Soft Tissue Bleeding Study",[39],"2011-01","2011-03","2009-08",91,[23],[120],{"nctId":151,"briefTitle":152,"status":60,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":159},"NCT01166243","The Fibrin Pad Liver Study",[39],"2011-08","2011-10","2010-07",84,[15],[120],{"trials":161,"activeCount":11},[],{"trials":163,"activeCount":11},[],{"intervention":165,"totalTrials":45,"cells":166},"EVICEL® Fibrin Sealant",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":195,"NA":197},{"trials":168,"activeCount":11},[],{"trials":170,"activeCount":11},[],{"trials":172,"activeCount":11},[],{"trials":174,"activeCount":11},[175,187],{"nctId":176,"briefTitle":177,"status":178,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT02309645","The Paediatric EVICEL® Neuro Study","TERMINATED",[39],"2021-08-17","2021-09-17","2014-10-01",40,[185],"CSF Leak",[165],{"nctId":188,"briefTitle":189,"status":60,"phases":190,"primaryCompletion":191,"completion":192,"start":62,"enrollment":183,"conditions":193,"interventions":194},"NCT02227706","The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study",[39],"2019-04-17","2019-05-17",[15,23],[165],{"trials":196,"activeCount":11},[],{"trials":198,"activeCount":11},[],{"intervention":200,"totalTrials":45,"cells":201},"EVICEL Fibrin Sealant",{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":219,"PHASE4":231,"NA":233},{"trials":203,"activeCount":11},[],{"trials":205,"activeCount":11},[],{"trials":207,"activeCount":11},[208],{"nctId":209,"briefTitle":210,"status":60,"phases":211,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"NCT01589822","The EVICEL® Gastrointestinal Study",[38],"2014-01","2014-09","2012-06",214,[217],"Gastrointestinal Diseases",[200],{"trials":220,"activeCount":11},[221],{"nctId":222,"briefTitle":223,"status":60,"phases":224,"primaryCompletion":225,"completion":226,"start":98,"enrollment":227,"conditions":228,"interventions":230},"NCT02457546","The EVICEL® Neurosurgery Phase III Study",[39],"2017-09-13","2017-10-12",234,[229],"Cerebrospinal Fluid Leak",[200],{"trials":232,"activeCount":11},[],{"trials":234,"activeCount":11},[],{"intervention":236,"totalTrials":45,"cells":237},"EVARREST® Fibrin Sealant Patch",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":266,"NA":268},{"trials":239,"activeCount":11},[],{"trials":241,"activeCount":11},[],{"trials":243,"activeCount":11},[],{"trials":245,"activeCount":11},[246,255],{"nctId":247,"briefTitle":248,"status":60,"phases":249,"primaryCompletion":250,"completion":213,"start":251,"enrollment":252,"conditions":253,"interventions":254},"NCT01993888","The EVARREST® Fibrin Sealant Patch Liver Study",[39],"2014-07","2013-10",102,[15],[236],{"nctId":256,"briefTitle":257,"status":60,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NCT03255174","The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study",[39],"2025-01-22","2025-02-14","2018-03-20",35,[264],"Controlling Mild to Moderate Bleeding During Surgery",[236],{"trials":267,"activeCount":11},[],{"trials":269,"activeCount":11},[],{"intervention":105,"totalTrials":45,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":289,"PHASE4":295,"NA":297},{"trials":273,"activeCount":11},[],{"trials":275,"activeCount":11},[],{"trials":277,"activeCount":11},[278],{"nctId":279,"briefTitle":280,"status":60,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},"NCT01681030","The Fibrin Pad Cardiovascular Study",[38],"2013-08-01","2013-09-03","2012-08-01",42,[103],[288,105],"EVARREST™",{"trials":290,"activeCount":11},[291],{"nctId":95,"briefTitle":96,"status":60,"phases":292,"primaryCompletion":98,"completion":99,"start":100,"enrollment":101,"conditions":293,"interventions":294},[39],[103],[84,105],{"trials":296,"activeCount":11},[],{"trials":298,"activeCount":11},[],{"intervention":300,"totalTrials":301,"cells":302},"Fibrin sealant",1,{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":320,"NA":322},{"trials":304,"activeCount":11},[],{"trials":306,"activeCount":11},[],{"trials":308,"activeCount":11},[],{"trials":310,"activeCount":11},[311],{"nctId":312,"briefTitle":313,"status":60,"phases":314,"completion":315,"start":316,"enrollment":114,"conditions":317,"interventions":319},"NCT00154141","Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures",[39],"2006-03","2005-06",[318],"Peripheral Vascular Disease",[300],{"trials":321,"activeCount":11},[],{"trials":323,"activeCount":11},[],{"intervention":325,"totalTrials":301,"cells":326},"EVARREST™ Sealant Matrix",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":345,"NA":347},{"trials":328,"activeCount":11},[],{"trials":330,"activeCount":11},[],{"trials":332,"activeCount":11},[],{"trials":334,"activeCount":11},[335],{"nctId":336,"briefTitle":337,"status":60,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":183,"conditions":342,"interventions":344},"NCT02227992","The EVARREST® Paediatric Mild\u002FModerate Liver and Soft Tissue Bleeding Study",[39],"2021-10-27","2021-11-12","2014-07-01",[15,23,343],"Hepatic Parenchyma Bleeding",[325],{"trials":346,"activeCount":11},[],{"trials":348,"activeCount":11},[],{"intervention":350,"totalTrials":301,"cells":351},"Human Thrombin",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":371,"NA":373},{"trials":353,"activeCount":11},[],{"trials":355,"activeCount":11},[],{"trials":357,"activeCount":11},[],{"trials":359,"activeCount":11},[360],{"nctId":361,"briefTitle":362,"status":60,"phases":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT00196534","A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery",[39],"2006-07","2004-11",304,[368],"Cardiovascular, Neurologic (Spine), and General Surgery",[350,370],"Bovine Thrombin",{"trials":372,"activeCount":11},[],{"trials":374,"activeCount":11},[],{"intervention":370,"totalTrials":301,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":389,"NA":391},{"trials":378,"activeCount":11},[],{"trials":380,"activeCount":11},[],{"trials":382,"activeCount":11},[],{"trials":384,"activeCount":11},[385],{"nctId":361,"briefTitle":362,"status":60,"phases":386,"completion":364,"start":365,"enrollment":366,"conditions":387,"interventions":388},[39],[368],[350,370],{"trials":390,"activeCount":11},[],{"trials":392,"activeCount":11},[],{"intervention":394,"totalTrials":301,"cells":395},"Evicel",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":413,"NA":415},{"trials":397,"activeCount":11},[],{"trials":399,"activeCount":11},[],{"trials":401,"activeCount":11},[],{"trials":403,"activeCount":11},[404],{"nctId":405,"briefTitle":406,"status":60,"phases":407,"primaryCompletion":408,"completion":155,"start":156,"enrollment":409,"conditions":410,"interventions":412},"NCT01174992","A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair",[38,39],"2011-09",139,[411],"Dura Defects",[394],{"trials":414,"activeCount":11},[],{"trials":416,"activeCount":11},[],{"intervention":418,"totalTrials":301,"cells":419},"Fibrin Sealant 2",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":438,"NA":440},{"trials":421,"activeCount":11},[],{"trials":423,"activeCount":11},[],{"trials":425,"activeCount":11},[],{"trials":427,"activeCount":11},[428],{"nctId":429,"briefTitle":430,"status":60,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":437},"NCT00307515","Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery",[39],"2006-12","2006-02",135,[436],"Blood Loss, Surgical",[418],{"trials":439,"activeCount":11},[],{"trials":441,"activeCount":11},[],{"intervention":288,"totalTrials":301,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":445,"activeCount":11},[],{"trials":447,"activeCount":11},[],{"trials":449,"activeCount":11},[450],{"nctId":279,"briefTitle":280,"status":60,"phases":451,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":452,"interventions":453},[38],[103],[288,105],{"trials":455,"activeCount":11},[],{"trials":457,"activeCount":11},[],{"trials":459,"activeCount":11},[],{"intervention":461,"totalTrials":301,"cells":462},"REGRANEX",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":473},{"trials":464,"activeCount":11},[],{"trials":466,"activeCount":11},[],{"trials":468,"activeCount":11},[],{"trials":470,"activeCount":11},[],{"trials":472,"activeCount":11},[],{"trials":474,"activeCount":11},[475],{"nctId":476,"briefTitle":477,"status":60,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT00518102","The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])",[],"2005-05","2003-01",4431,[483],"Diabetes Mellitus",[461],{"intervention":486,"totalTrials":301,"cells":487},"EVICEL ™ Fibrin Sealant",{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":494,"PHASE4":496,"NA":498},{"trials":489,"activeCount":11},[],{"trials":491,"activeCount":11},[],{"trials":493,"activeCount":11},[],{"trials":495,"activeCount":11},[],{"trials":497,"activeCount":11},[],{"trials":499,"activeCount":11},[500],{"nctId":501,"briefTitle":502,"status":60,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":509},"NCT01158261","The Evicel Post-Authorization Surveillance Study",[],"2014-04","2014-05","2010-06",300,[318,15],[486]]